Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (383)	12/8/2003 5:47:57 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 523

Th's NRGN, I was bit concerned with different media reports, and someone was doing this intentionally. Press Release Source: Neurogen Corporation Neurogen Corrects Media Report on Merck Alliance Monday December 8, 3:22 pm ET BRANFORD, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Neurogen Corporation (Nasdaq: NRGN - News) today corrected a media report concerning its exclusive worldwide alliance with Merck & Co., Inc. to develop next-generation drugs for pain and other disorders, which was announced on December 1, 2003. A media report today incorrectly stated that Neurogen was not eligible to receive milestone payments and royalties on one compound that originated with Merck's research. In fact, the companies are pooling all VR1 drug candidates previously discovered by each company and Neurogen is eligible to receive identical milestone payments and royalties on all VR1 compounds discovered by either party prior to or during the exclusive collaboration with the exception of a single early milestone payment. While this single milestone payment would not be owed on one candidate Merck is bringing to the collaboration, Neurogen is eligible to receive all other milestone payments and royalties on this compound and on any other compound in the collaboration.